TP53 and neoplasm: Moreover, MIRA-1 [706] and STIMA-1 [681], as well as APR-246 [695] and PK11007 [709], are able to exert their anti-tumor potential not only through restoring mutant p53 but also via targets, such as cellular redox regulators.